Yousif Capital Management LLC Has $528,000 Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Yousif Capital Management LLC cut its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 1.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,358 shares of the company’s stock after selling 325 shares during the period. Yousif Capital Management LLC’s holdings in Harmony Biosciences were worth $528,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of HRMY. China Universal Asset Management Co. Ltd. raised its stake in Harmony Biosciences by 95.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,533 shares of the company’s stock worth $50,000 after acquiring an additional 748 shares in the last quarter. Oakworth Capital Inc. acquired a new stake in shares of Harmony Biosciences during the 3rd quarter worth about $150,000. ELCO Management Co. LLC bought a new position in Harmony Biosciences during the 3rd quarter valued at about $210,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Harmony Biosciences in the fourth quarter valued at about $210,000. Finally, Raymond James & Associates bought a new stake in Harmony Biosciences during the 3rd quarter worth about $216,000. Institutional investors own 86.23% of the company’s stock.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 11,979 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $32.00, for a total transaction of $383,328.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 30.80% of the stock is owned by insiders.

Harmony Biosciences Price Performance

Shares of HRMY opened at $31.57 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.72 and a current ratio of 3.11. The stock has a 50 day simple moving average of $31.17 and a 200 day simple moving average of $30.18. Harmony Biosciences Holdings, Inc. has a 52-week low of $18.61 and a 52-week high of $39.26. The firm has a market capitalization of $1.79 billion, a PE ratio of 13.67, a P/E/G ratio of 0.43 and a beta of 0.75.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.07. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. The business had revenue of $154.62 million during the quarter, compared to analyst estimates of $154.10 million. During the same period in the previous year, the firm earned $0.48 EPS. Harmony Biosciences’s quarterly revenue was up 29.8% compared to the same quarter last year. Sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 2.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on HRMY shares. Cantor Fitzgerald reissued an “overweight” rating and set a $49.00 price objective on shares of Harmony Biosciences in a report on Friday, April 12th. Mizuho dropped their price objective on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 30th. Finally, The Goldman Sachs Group upped their price target on Harmony Biosciences from $25.00 to $28.00 and gave the company a “sell” rating in a research note on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.63.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.